Ann: PYC Corporate Presentation - February 2023, page-9

The comprehensive presentation has all the makings to be prepared for brokers and financial backers.
A financial arrangement seems to be on the horizon for which this presentation can function as a base information sheet.

The fine balance between scientifically informative whilst being easily understood and structured for
financial departments gives away its purpose.


IND submission just initiated, received end of Feb / early March will bring the FDA response which should lead
to a whole array of announcements. The equal weight in presenting all three lead programs points towards
funding as we are nowhere near funded for even one of of them to see us through to market.
Was 2021 too early for the company to commit to a sell out of its IP and assets, now might be the time to revisit
those contacts made back then.
In my opinion, that is exactly the reason why we are parked at current undervalued levels.

The FDA response could be the final condition for one of those US based investors/ partners, we presented to in 2021, to meaningfully engage.

all IMO.